INSP — Inspire Medical Systems, Inc.

Inspire Medical Systems (INSP) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Decreased 7.6% year-over-year to $200.6 million, primarily due to coding and reimbursement disruptions.
• Adjusted Operating Income: Improved due to cost discipline, but adjusted operating margin declined due to lower sales.
• Diluted EPS: Reported at $0.01; adjusted diluted EPS at $0.14.
• Operating Cash Flow: $23.2 million for the quarter, $36.1 million year-to-date, an improvement of $40 million compared to the prior year.
• Balance Sheet: Strong position with no debt and $415 million in cash and investments.

2. Strategic Updates and Business Highlights

• Project Horizon: Announced as a strategic growth initiative aimed at enhancing patient flow and revenue growth. Expected to create $30 million of annualized growth investment capacity through restructuring, including supply chain optimization.
• Coding and Reimbursement: Improved clarity and education efforts are underway, particularly with high-volume centers. Positive trends in prior authorization submissions noted.
• Clinical Outcomes: Positive data from the Inspire V trial presented at the American Academy of Sleep Medicine Conference, highlighting safety, efficacy, and cardiovascular health benefits of Inspire therapy.
• International Growth: Notable increase in international sales, particularly in Continental Europe, driven by new reimbursements in France.

3. Forward Guidance and Outlook

• Revenue Outlook: Revised full-year revenue guidance to $835 million to $875 million, reflecting ongoing coding and reimbursement challenges.
• Profitability Metrics: Adjusted operating margin expected to be in the range of 4% to 6%. Adjusted diluted EPS guidance revised to a loss of $0.42 to earnings of $0.17.
• Third Quarter Expectations: Forecasting an 8% to 10% year-over-year revenue decline, with breakeven adjusted operating income anticipated.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The 7.6% decrease in revenue reflects ongoing disruptions in coding and reimbursement, with an estimated total impact of $120 million to $130 million for the year.
• High Effective Tax Rate: The effective tax rate was reported at 89.9%, primarily due to stock-based compensation impacts.
• Utilization Concerns: Some centers paused procedures due to confusion over coding, leading to a backlog in patient procedures.
• Competitive Pressures: Although no immediate impact was reported from competitors, there is an acknowledgment of potential future competition.

5. Notable Q&A Insights

• Utilization Trends: Management noted that while there are challenges, they are seeing improvements in prior authorization submissions, which is a leading indicator for future procedure volumes.
• Project Horizon Details: The initiative aims to streamline operations and improve patient flow, with expected benefits more visible in 2027.
• International Growth Drivers: The increase in international sales is attributed to focused efforts in key European markets and new reimbursement approvals.
• GLP-1 Impact: Management believes GLP-1 medications will help patients qualify for Inspire therapy but do not expect a significant immediate impact on overall demand.
• Backlog Management: There is confidence that as coding clarity improves, the backlog of patients waiting for procedures will begin to clear.

This summary encapsulates the key aspects of Inspire Medical Systems' Q2 2026 earnings call, highlighting both the challenges faced and the strategic initiatives in place to drive future growth.